Key Inclusion Criteria:

          -  For the FL grade 1-3a cohort only: Central histopathologic confirmation of the FL
             Grade 1 to 3a diagnosis must be obtained before study enrollment. Patients with FL
             grade 3b are ineligible for this cohort but may be included in the "other B-NHL"
             cohort. Follicular lymphoma subtyping is based on the World Health Organization (WHO)
             classification (Swerdlow, 2017).

          -  Disease-specific cohorts that has relapsed after or is refractory to at least 2 prior
             lines of systemic therapy as defined in the protocol

          -  DLBCL cohort: Patients with DLBCL that has relapsed after or is refractory to at least
             2 prior lines of systemic therapy as defined in the protocol

          -  MCL after BTK inhibitor therapy cohort: New enrollment is paused until further notice

          -  MZL cohort: New enrollment is paused until further notice

          -  Other B-NHL cohort: Patients with B-NHL other than FL grade 1-3a, DLBCL, MCL, or MZL
             that has relapsed after or is refractory to at least 2 prior lines of systemic therapy
             as defined in the protocol. New enrollment stopped for patients with Burkitt lymphoma
             and Burkitt-like lymphoma.

          -  Patients should in the judgment of the investigator require systemic therapy for
             lymphoma at the time of study enrollment

          -  Measurable disease on cross sectional imaging as defined in the protocol documented by
             diagnostic imaging (computed tomography (CT), or magnetic resonance imaging (MRI))

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Adequate bone marrow, hepatic, and renal function as defined in the protocol

        Key Exclusion Criteria:

          -  Primary central nervous system (CNS) lymphoma or known involvement by non-primary CNS
             Non-Hodgkin Lymphoma (NHL) (suspected CNS lymphoma should be evaluated by lumbar
             puncture, as appropriate, in addition to the mandatory head CT or MRI).

          -  Treatment with any systemic anti-lymphoma therapy within 5 half-lives or within 28
             days prior to first administration of study drug, whichever is shorter.

          -  History of allogeneic stem cell transplantation

          -  Prior treatment with any chimeric antigen receptor T-cell (CAR-T) therapy

          -  Continuous systemic corticosteroid treatment with more than 10 mg per day of
             prednisone or anti-inflammatory equivalent within 72 hours of start of study drug

          -  History of neurodegenerative condition or CNS movement disorder. Patients with a
             history of seizure within 12 months prior to study enrollment are excluded

          -  Another malignancy except B-NHL in the past 5 years, with the exception of
             non-melanoma skin cancer that has undergone potentially curative therapy or in situ
             cervical carcinoma, or any other tumor that has been deemed to be effectively treated
             with definitive local control and with curative intent.

          -  Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or
             hepatitis C infection; or other uncontrolled infection as defined in the protocol

          -  Known hypersensitivity to both allopurinol and rasburicase

          -  Prior treatment with an anti-CD20 x anti-CD3 bispecific therapy

        Note: Other protocol-defined Inclusion/Exclusion criteria apply